-
Mashup Score: 3
A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma @DarrenPanMD @UCSFCancer #MMSM https://t.co/jaeTM6KLTR
-
-
Mashup Score: 15Are transplant strategies in relapsed myeloma relevant in the cellular treatment era? - 2 day(s) ago
Transplant strategies in multiple myeloma, both frontline and salvage, are being redefined within the evolving treatment landscape. Allogeneic stem cell transplantation has no role in the modern trea…
Categories: General Medicine NewsTweet-
Are transplant strategies in relapsed myeloma relevant in the cellular treatment era? Drs. Despina Fotiou and Efstathios Kastritis of the University of Athens comment on recent work from Heinz Ludwig MD et al. https://t.co/mOX4uTpGbE @oncoalert @IMFmyeloma @uoaofficial #mmsm https://t.co/PcStsw8GnK
-
-
Mashup Score: 4
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH; Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma. #mmsm https://t.co/zLTR5VILEZ
-
-
Mashup Score: 5
During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma. #mmsm | @PennMedicine @PennCancer @AlGarfall https://t.co/sGCsmtfSwH
-
-
Mashup Score: 2Dr Voorhees Highlights Durability of Cilta-Cel in Myeloma - 3 day(s) ago
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
WATCH: Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma. #mmsm | @AtriumHealth https://t.co/cX9IOBurNi
-
-
Mashup Score: 5
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma. #mmsm https://t.co/wP9UrnBeo8
-
-
Mashup Score: 5Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens - 4 day(s) ago
Key Points. BCMA antigen expression is controlled by the ubiquitin-proteasome system in a p97-dependent manner at the plasma membraneElevation of BCMA cell
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
2/ link to @BloodPortfolio #MMsm paper. I must say that I love the “CarCAR” name for carfilzomib following CAR-T. Yes, all our drug names sound similar but we make the most of it! https://t.co/NMztrABW1p
-
-
Mashup Score: 3Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma - 5 day(s) ago
Panelists discuss how subcutaneous anti-CD38 monoclonal antibodies are reshaping frontline multiple myeloma treatment by improving efficacy, tolerability, and patient convenience across both transplant-eligible and ineligible populations.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Recent advancements in the treatment of newly diagnosed multiple myeloma have significantly reshaped clinical strategies, particularly in both transplant-eligible and transplant-ineligible populations. Watch an expert discussion on it: #mmsm https://t.co/4mOnlOk9Qb
-
-
Mashup Score: 8
Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
"What makes ISB 2001 unique and distinctly different from other traditional bispecific antibodies is, firstly, the dual and high-affinity binding to CD38 and BCMA," said Hang Quach, MBBS, MD, FRACP, FRCPA. #mmsm | @HangQuach1 https://t.co/3De225z61W
-
The 2-year survival rate was 55% in patients with multiple myeloma who received anti-BCMA agents and 51% in patients who received anti-GPRC5D agents (P = .76); complete remission was observed in 37% and 35%, respectively. #mmsm https://t.co/4dbM50Dnfo